Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...

Anebulo Pharmaceuticals (NASDAQ:ANEB) is developing a novel antidote for cannabinoid intoxication and, longer term, other indications related to abuse and addiction.

Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-held Trasir Therapeutics as a steppingstone for a strategic repositioning to focus on development of RNA therapeutics, while in the medium...

As CEO of closely-held GeneTether, Har Grover is tackling the emerging potential of gene editing, which has come alive in the past few years. As an entrepreneur, investor, senior executive and strategist with over 30...

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) is using artificial intelligence to enable early detection of cognitive decline in neurodegenerative disorders, such as dementia and Alzheimer’s disease, the leading...

As president, a co-founder and CEO of closely-held NeoVentures Biotechnology, Gregory Penner, Ph.D., took a different route developing aptamers for healthcare solutions. His training was in quantitative genetics of crop...

Closely-held Azura Ophthalmics is developing the first ophthalmic keratolytics for the treatment of lid margin diseases, such as Meibomian gland dysfunction (MGD), blepharitis, dry eye disease and contact lens...

As CEO of InfoBionic, a closely-held digital health company with an initial focus on cardiac arrhythmia detection and monitoring, Stuart Long knows his way around achieving commercial growth in the medical device market...

Closely-held ViaCyte, a company with two decades of experience, is utilizing pluripotent stem cell technology and novel delivery approaches to address multiple disease areas, with an initial focus and lead products...